Abrocitinib 200 MG Oral Tablet — Competitive Intelligence Brief

Abrocitinib 200 MG Oral Tablet (abrocitinib-200-mg-oral-tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: JAK inhibitor.

marketed JAK inhibitor JAK1 Small molecule

Target snapshot

Abrocitinib 200 MG Oral Tablet (abrocitinib-200-mg-oral-tablet) — Pfizer. Abrocitinib 200 MG Oral Tablet is a small molecule that targets the JAK1 protein.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Abrocitinib 200 MG Oral Tablet TARGET	abrocitinib-200-mg-oral-tablet	Pfizer	marketed	JAK inhibitor	JAK1
Leqselvi	DEURUXOLITINIB	Sun Pharm Inds Inc	marketed		JAK1, JAK2, TYK2	2024-01-01
Cibinqo	Abrocitinib	Pfizer	marketed	Janus Kinase Inhibitor [EPC]	Tyrosine-protein kinase JAK1	2022-01-01
Cibinqo	abrocitinib	Pfizer	marketed	Janus Kinase Inhibitor [EPC]	Tyrosine-protein kinase JAK1	2022-01-01
ABROCITINIB	ABROCITINIB		marketed	Janus Kinase Inhibitor [EPC]	JAK1	2021-01-01
Jyseleca	FILGOTINIB	Gilead Sciences Ireland UC	marketed		Tyrosine-protein kinase JAK1	2020-01-01
Chronic- PF-06480605 150 mg SC Q4W	chronic-pf-06480605-150-mg-sc-q4w	Pfizer	marketed	Janus kinase inhibitor	JAK1 and JAK2 enzymes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (JAK inhibitor class)

1. Pfizer · 19 drugs in this class
2. Aclaris Therapeutics, Inc. · 2 drugs in this class
3. Beijing Friendship Hospital · 2 drugs in this class
4. Azienda Ospedaliero, Universitaria Pisana · 1 drug in this class
5. CAGE Bio Inc. · 1 drug in this class
6. CTI BioPharma · 1 drug in this class
7. Celgene · 1 drug in this class
8. Fred Hutchinson Cancer Center · 1 drug in this class
9. LEO Pharma · 1 drug in this class
10. McMaster University · 1 drug in this class